RecruitingNCT01341327
Observational Study for Left Main Disease Treatment
A GLOBAL, MULTICENTER, PROSPECTIVE, REAL WORLD OBSERVATIONAL STUDY FOR LEFT MAIN DISEASE TREATMENT
Sponsor
Seung-Jung Park
Enrollment
10,000 participants
Start Date
Jul 1, 2007
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to observe clinical courses for long-term in patients with unprotected LMCA disease and to evaluate comparative results of medical treatment, coronary stenting with drug-eluting stents, and CABG for the treatment of an unprotected LMCA stenosis in the "real world" daily practice.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Significant unprotected left main stenosis (>50% by visual estimation)
- The LMCA is considered unprotected if there are no patent coronary artery bypass grafts to the left anterior descending artery or the left circumflex artery.
- No limitation of clinical or lesion characteristics
- Age >18 years
- The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site.
Exclusion Criteria1
- Protected left main stenosis
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(42)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT01341327
Related Trials
DEBSCAN-IVL. Drug Eluting Balloon or Drug Eluting Stent to Treat CAlcified Nodules After IntraVascular Lithotripsy.
NCT0665783313 locations
Product Surveillance Registry
NCT01524276395 locations
Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions
NCT072582901 location
Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions
NCT0719069016 locations
Ultrathin Strut Sirolimus-eluting Stent With Bioabsorbable Polymer in Patients Receiving Chronic Oral Anticoagulation
NCT0686315512 locations